Merger Creates Global Leader in Low-dose Carbon Monoxide Therapy for PF

Merger Creates Global Leader in Low-dose Carbon Monoxide Therapy for PF

Proterris and Alfama recently announced a merger of the two companies which will effectively create the world’s leader in the field of carbon monoxide (CO) therapies for acute and chronic diseases, such as pulmonary fibrosis. “The merger of Alfama with Proterris represents a very synergistic and strategic fit between two…

7 Common Questions About Ofev

Ofev (nintedanib) is a treatment used for patients with idiopathic pulmonary fibrosis (IPF).  It is an anti-fibrotic drug that was approved by the FDA in October 2014 to help slow down the progression of the disease. Here are some of the most frequently asked questions about Ofev from the manufacturers, Boehringer Ingelheim. How…

Bellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study Finds

INOpulse has shown promise in treating patients with pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF), concludes a study by Bellerophon Therapeutics, developer of the inhaled nitrous oxide device. The study, “Unraveling the Mode of Action of Pulsed Inhaled NO in Severe IPF Using Functional Respiratory Imaging.” showed that PH-IPF…